Ascites

02/01/2015 - "Most patients (77.6%) completely cleared the ascites without diuretics, but many achieved this beyond 2 years. "
06/02/1978 - "Six patients showed partial remission defined as decrease of tumour mass by more than 50% or as almost complete disappearance of ascites during more than two months without concomitant diuretic treatment. "
01/01/1996 - "This difference was mainly due to a significant reduction in infectious complications (PN 17% vs control 37%; p = 0.01), and in the need for diuretic drugs to control ascites (PN 25% vs control 50%; p = 0.004). "
07/01/1994 - "After diuretic treatment, we observed a significant reduction of ascites volumes (from 9.0 +/- 0.98 to 4.9 +/- 0.6 litres; p < 0.0005), IAP (from 17.5 +/- 1.3 to 11.3 +/- 0.8 cmH2O; p < 0.0005) and FWPC (from 99.8 +/- 6.7 to 76.2 +/- 6.6 ml/min; p < 0.001). "
08/01/2015 - "Large volume paracentesis is found to be safer and more effective for the treatment of tense ascites compared with larger-than-usual doses of diuretics according to studies. "

11/01/2021 - "Good ECOG performance status before drainage, albumin level ≥ 35 g/L, successful drainage, absence of ascites, and post-drainage treatment were identified as factors of improved survival in univariate analysis. "
11/01/2011 - "Albumin infusion (8g of albumin/L of ascites removed) is effective in preventing it, but high costs and scant availability limit its use. "
03/07/2006 - "Median follow-up was 84 (2-120) mo. Albumin-treated patients had significantly greater cumulative survival rate (Breslow test=7.05, P=0.0078) and lower probability of ascites recurrence (51% versus 94%, P<0.0001). "
08/01/1992 - "The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites."
11/01/2011 - "This unblinded, randomized, pilot study suggests that treatment with half doses of albumin is effective in the prevention of paracentesis-induced circulatory dysfunction and its related clinical complications in cirrhotic patients with tense ascites treated by large volume paracentesis. "

06/01/2015 - "No significant correlation between improved scores and the amount of reinfused protein or ascites removed was observed. "
09/01/2010 - "In case of urinary ascites, the serum beta2 microglobuline rate could be improved in relation with the transperitoneal reabsorption of this protein."
01/01/2009 - "Although the serological abnormalities with SLE had normalized and urinary protein almost disappeared on the 51th hospital day, the ascites had not improved at all. "
06/01/2021 - "Our study identified patients with ascites and a poor prognosis by measuring microfibrillar associated protein 4 (MFAP4), a protein present in the abdominal fluid. "
06/01/2018 - "This study identified and verified protein markers that can distinguish malignant ascites with or without peritoneal seeding from benign ascites. "

10/01/2010 - "Cisplatin administration in the peritoneal cavity is thus very effective in preventing progression of ascites."
01/01/2021 - "In this study, we explored anoikis escape, cisplatin resistance, and prosurvival signaling as a function of the αvß3 transmembrane conformational activation state in cells suspended in ascites. "
03/01/1995 - "To study the effect of thermotolerance on cellular cisplatin (cDDP) sensitivity at 37 degrees C and 43 degrees C in cell lines with different cDDP sensitivities, two Ehrlich ascites tumour cell lines (one with high cDDP sensitivity and one with in vitro acquired cDDP resistance) were used. "
01/01/2023 - "Qigu Zhushui decoction can reduce the malignant ascites in mice, and the combination of Qigu Zhushui decoction and cisplatin has a significant anti-malignant ascites effect, which can significantly prolong the survival time and improve the survival rate."
12/01/2021 - "We identified that CD11b+ cells from the ascites of mice that have been treated with cisplatin elicits an increase in IFN-ɣ expression from CD8+ T-cells compared to CD11b+ cells from a mouse treated with vehicle control (604.0 pg/mL v. 4328.0 pg/mL; p < .0001). "

01/01/2020 - "The aim of this meta-analysis was to evaluate whether response to treatment with tolvaptan is associated with improved overall survival in cirrhotic patients with refractory ascites. "
11/01/2015 - "We evaluated the therapeutic efficacy and safety of tolvaptan administration to treat refractory ascites. "
11/01/2013 - "Tolvaptan had therapeutic efficacy in the reduction of ascites in rats with chronic liver injury. "
12/01/2021 - "In this study, we conducted a genome-wide association study (GWAS) in the Japanese population to identify genetic variants associated with tolvaptan's efficacy for patients with hepatic ascites. "
04/01/2019 - "Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites."

07/25/2022 - "Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites."
05/01/2008 - "In vitro release studies of paclitaxel from the implant were conducted in various fluids including human ascites fluid. "
01/01/2023 - "The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. "
01/01/2018 - "The proportion of patients who started with a reduced dose of paclitaxel was higher for patients with massive ascites than others. "
05/01/2014 - "Three cycles of weekly paclitaxel were successfully administered, leading to the disappearance of malignant ascites. "

10/01/2004 - "Modifying MELD, by including points for persistent ascites and low serum sodium, improved prediction of early pretransplant mortality in low MELD score patients. "
02/01/2000 - "There is improved understanding of the mechanism of ascites formation and the pathophysiology of the renal sodium retention that accompanies portal hypertensive ascites. "
03/01/1999 - "Adequate intravascular filling in ascites-free cirrhotic patients with normal portal pressure permits an improved but not normalized renal response to a sodium load, possibly due to persistently elevated sympathetic activity. "
08/01/1998 - "In conclusion, URO improved sodium and urine output in cirrhotic patients with and without ascites by enhancing fluid delivery from the proximal tubules in addition to inhibiting fractional sodium reabsorption in the distal nephron."
05/10/2016 - "However, some randomized controlled trials have suggested a lack of benefit with a sodium-restricted over an unrestricted diet, and even an increase in ascites and renal complications has been reported. "

01/01/2020 - "Activation of the RAAS contributes to the pathophysiology of intrahepatic PH in dogs, suggesting that spironolactone may not only be effective for the treatment of ascites but also for the suppression of intrahepatic PH."
03/01/1997 - "Five patients (three in the placebo and two in the spironolactone group) abandoned the treatment prior to ascites recurrence or the end of the study due to complications or lack of compliance. "
05/14/1961 - "[Trials of treatment of cirrhotic ascites with a spirolactone. "
08/01/2003 - "Since spironolactone alone requires less dose adjustment, it would be more suitable for treating ascites on an outpatient basis."
01/01/2002 - "In cirrhotic patients with ascites and marked activation of sympathetic nervous system, spironolactone (200 mg/day) is unable to mobilize ascites. "

05/15/2012 - "In the prospective study of actual 15 LDLT, using VP-RL with types B and C, size and number of venous reconstructions, and functional GV and postoperative parameters, such as postoperative serum total bilirubin levels and ascites volume, were significantly improved compared with those using M-RL (P<0.05). "
01/01/2008 - "Significant factors for improved DFS: absence vs. presence of ascites (16 vs. 5 mos, p=0.02), Bilirubin <2 vs. > or = 2 (14 vs. 5 mos, p=0.0278), AFP <400 vs. > or = 400 (15 vs. 4 mos, p=0.0025), Child-Pugh Grade (A = 16, B = 10, C = 3 mos, p=0.03). "
07/01/2009 - "A meso-caval shunt was performed, after which the ascites resolved, serum bilirubin normalized and the synthetic function of the liver improved. "
01/01/2008 - "Univariate analysis demonstrated improved OS for the absence vs. presence of ascites (31 vs. 15 mos, p=0.003), Bilirubin <2 mg/dl vs. > or = 2 mg/dl (27 vs. 19 mos, p=0.01), AFP <400 vs. > or = 400 (29 vs. 13 mos, p<0.0001) and Child-Pugh Grade (A = 28, B = 15, C = 5 mos, p=0.01). "
09/22/2001 - "In our study, age, an increase in bilirubin level, presence of ascites, and marital status (single, widowed or separated) were associated with a significantly lower survival rate in chronic alcoholics."

09/01/2018 - "The present data revealed a significant reduction in ascites volume and cell count in mice that were treated with P-5m plus 5-Fu. "
01/01/2015 - "SL-A002 demonstrated significant dose-dependent antitumor activity in the Sarcoma-180 (S-180) ascites model with peak effect produced at the dose of 120 mg/kg (i.p.) with inhibition of 89.36% compared to 97.96% for 5-FU (20 mg/kg i.p.). "
02/01/2011 - "Assessing gene expression would be useful in predicting 5-FU sensitivity for patients with malignant ascites."
05/01/2010 - "Blood and ascites samples were collected at different times to detect 5-FU quantity by HPLC. "
05/01/2010 - "To investigate pharmacokinetics and potency of antitumor activity of a novel 5-fluorouracil carrier erythrocyte (RBC-FU) in mice bearing malignant ascites. "

12/01/2018 - "After 1 course of this therapy, CT revealed complete disappearance of ascites and significant reduction in the size of the peritoneal dissemination. "
07/01/2015 - "He was referred for ¹⁷⁷Lu-[DOTA⁰,Tyr³]octreotate (DOTATATE) therapy, and after 4 induction cycles, his ascites resolved completely, and his metastatic disease stabilized. "
06/01/1999 - "With multidrug anti-MAC therapy the ascites resolved completely, and the patient has survived for >21 months. "
08/01/1991 - "We describe two patients with clinical ascites that resolved completely on thyroid replacement therapy. "
11/01/2022 - " This study confirms a good outcome for patients with AOGCT. They require long-term follow-up as late recurrences can occur many years post definitive therapy. The presence of ascites and elevated preoperative CA 125 levels were associated with a higher risk of recurrence and poor prognosis. "

01/01/2022 - "TIPS led to a remarkable improvement in the control of ascites in all CKD stages and no significant differences in TFS were recorded. "
01/10/2021 - "The patients experienced complete resolution or noticeable reduction of ascites (P < 0.001), significant reduction of liver size (16.7 ± 2.2 vs. 13.7 ± 1.7 cm, P = 0.018), and significant enlargement of the portal trunk (10.7 ± 2.5 vs. 13.4 ± 2.4 mm, P = 0.017) after TIPS compared to the pre-TIPS state. "
10/01/2013 - "In the TIPS group, ascites resolved completely, and liver congestion and function were relieved greatly in all three patients. "
10/01/1999 - "A TIPS was successfully placed with a rapid and complete resolution of ascites and marked improvement of his clinical condition. "
03/20/1996 - "Five out of 12 patients (41.7%) with refractory ascites were treated successfully by TIPS (complete resolution of ascites after three months: n = 4, significant reduction of ascites: n = 1). "

01/01/2021 - "Chemotherapy may be effective in reducing the negative impact of positive ascites cytology on the prognosis of patients in terms of progression-free and overall survivals, while complete staging surgery did not improve the prognosis of patients with positive ascites cytology. "
01/01/2019 - "This infiltrate had likely led to increased portal pressure attended by ascites formation, which resolved completely after chemotherapy. "
06/01/2012 - "After successful percutaneous stenting and placement of an internal-external drainage tube from the biliary tree to the gastric ventricle, ascites and cholascos resolved completely and the patient was then referred for chemotherapy. "
12/01/2020 - "Current chemotherapy regimens suffer from the dilution of ascites and rapid metabolism limiting their therapeutic efficacy. "
06/01/2006 - "The KPS of the responders was improved significantly (P < 0.001), and the response of malignant ascites to intraperitoneal chemotherapy was demostrated as an independent prognostic factor by multi-variate analysis in this series. "

03/01/2002 - "Transjugular percutaneous intrahepatic portosystemic shunt (IPS) is associated with a marked decrease in portal pressure and consequently this technique has been used in the treatment of refractory ascites. "
01/01/2023 - "Specifically, we find that patients who have higher proportions of portosystemic shunting earlier in disease have an attenuated rise in HVPG, delayed onset of ascites, and less hemodynamic shifting after transjugular intrahepatic portosystemic shunt placement. "
10/01/2015 - "For patients with recurrent disease or graft rejection needing large volume paracentesis, the use of a transjugular intrahepatic portosystemic shunt may serve as a bridge to more definitive treatment (retransplant), although it may not be as effective for managing ascites as splenic artery embolization, arguably underused, which is emerging as a potential alternative treatment option. "
09/01/1996 - "While surgical portosystemic shunts have been reported to be useful in the treatment of severe hepatic VOD with intractable ascites, few of these patients are surgical candidates. "
03/01/2005 - "Transjugular intrahepatic portosystemic shunt improved severe ascites in 45% of patients (P = 0.03). "

02/01/2011 - "Here, we describe a case of malignant ascites managed by insertion of a Tenckhoff Catheter (TC), which resulted in successful symptomatic control and improvement in quality of life."
05/01/2017 - "The placement of a tunneled peritoneal drainage catheter has been shown to be effective in patients with malignant ascites. "
01/01/2016 - "Large-volume peritoneal drainage with an indwelling peritoneal catheter is safe and effective for patients with tense ascites. "
11/01/2011 - "Radiologically placed tunneled peritoneal catheter is safe and effective in palliation of symptomatic malignant ascites."
11/01/2010 - "Although the low number of patients in our series precludes generalizations, tunneled peritoneal catheters seem to be a safe and effective minimally invasive treatment for malignant ascites in terminal oncologic patients. "